Conversely, blocking the PD-1/PD-L1 signaling pathway may cause the reactivation of T cells that are specific for the SARS-CoV-2 spike protein, increasing cytokine release and resulting in clinical events [23].Concurrent treatment with ICIs has not been shown to increase the risk of developing severe immune-related adverse events after booster doses of the COVID-19 vaccine in a series of retrospective studies [24,25,26,27]. The gene discussed is CD274; the disease is COVID-19.